Monitor the final pricing and unit count when the prospectus is filed under Rule 424(b). The extreme warrant coverage (350%) and going concern status make this a distressed financing, any exercise of warrants would cause massive dilution. Track whether the company obtains warrant stockholder approval for full warrant exercise.
Executive Summary
Imunon filed an amended S-1 (S-1/A) including a securities purchase agreement, warrant agency agreement, placement agency agreement, and placement agent warrant form for a best-efforts registered direct offering of units consisting of common stock (or pre-funded warrants) and four tranches of warrants with up to 350% warrant coverage. The offering is highly dilutive, the company has a going concern qualification with only $6.9M cash as of June 30, 2026, and the per-unit price and number of units remain undisclosed placeholders.
Key Facts
- Offering of up to 20M units, each unit consisting of one share (or pre-funded warrant) plus Tranche A (0.5 share), Tranche B (1 share), Tranche C (1 share), and Tranche D (1 share) warrants, up to 350% warrant coverage.
- Per Unit Purchase Price is a placeholder ($______); aggregate proceeds unknown.
- Placement agent Maxim Group LLC receives 7.0% cash fee and 5.0% warrant coverage (110% of per-unit price, 5-year term, 180-day lock-up).
- Company has a going concern qualification with only $6.9M cash as of June 30, 2026 (from prior S-1 cross-filing context).
- Company also disclosed an asset purchase agreement to sell ThermoDox program for equity, milestones up to $16.5M, and tiered royalties (from prior S-1 cross-filing context).
- 90-day lock-up on further equity issuance if gross proceeds < $10M; 180-day ban on variable rate transactions (with 60-day ATM exception).
Financial Impact
Undisclosed amount; offering size placeholder. Highly dilutive given 350% warrant coverage and low cash base of $6.9M.
Risk Factors
- Extreme dilution from up to 350% warrant coverage on top of 20M base shares.
- Going concern qualification, only $6.9M cash as of June 2026; company may not survive without this offering.
- Placeholder pricing, no certainty on final terms until 424(b) filing.
- Asset sale of ThermoDox program may not generate near-term cash; milestones are contingent.
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-1/A Filing (Primary) | 0001493152-26-048776 |
| Exhibit: ex10-40.htm | 0001493152-26-048776 |
| Exhibit: ex1-1.htm | 0001493152-26-048776 |
| Exhibit: ex4-10.htm | 0001493152-26-048776 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 1d ago | S-1/A | $0.8720 | awaiting T+1 | awaiting T+1 | $0.8300 (+4.82%) |
Oct 27, 2026 1d ago | S-1 | $0.8762 $0.8301 | ▲ +5.26% | ▲ +5.61% | $0.8300 (+5.27%) |
Oct 27, 2026 1d ago | 8-K | $0.8762 $0.8301 | ▼ −5.26% | ▼ −5.61% | $0.8300 (−5.27%) |
Oct 21, 2026 7d ago | 8-K | $1.19 $1.25 | ▲ +5.04% | ▲ +6.22% | $0.8300 (−30.25%) |
Sep 29, 2026 29d ago | 8-K | $1.34 $1.29 | ▲ +3.37% | ▲ +3.17% | $0.8300 (+37.83%) |
Aug 11, 2026 11w ago | 8-K | $1.61 $1.58 | ▼ −1.86% | ▼ −2.56% | $0.8300 (−48.45%) |
Aug 11, 2026 11w ago | 8-K | $1.61 $1.61 | · 0.00% | ▼ −0.25% | $0.8300 (−48.45%) |
Jun 30, 2026 17w ago | 8-K | $1.88 $1.91 | ▲ +1.60% | ▲ +1.73% | $0.8300 (−55.85%) |
Jun 16, 2026 19w ago | 8-K | $1.86 $1.82 | ▼ −2.15% | ▼ −2.93% | $0.8300 (−55.38%) |
Jun 4, 2026 20w ago | 8-K | $2.10 $2.06 | ▲ +1.90% | ▼ −0.69% | $0.8300 (+60.48%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers